BMS: Delayed new drug to avoid paying billions?
World of DTC Marketing
FEBRUARY 25, 2022
Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. Was it a wise move or incompetence? According to a complaint in Manhattan federal court, Bristol Myers failed to use contractually required “diligent efforts” to win U.S.
Let's personalize your content